Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions display a mix of cautious optimism and skepticism, highlighting clinical improvements such as 68% showing better oxygen support, while emphasizing limitations like small sample sizes and adverse effects. The tone varies from supportive remarks like 'helpful in severe cases' to critical comments questioning safety and study validity, emphasizing the complex debate around remdesivir's role in treating severe Covid-19.
Most discussions recognize the study's findings of clinical improvement, indicating general support for remdesivir's potential.
The high interest is shown through detailed analysis and references to multiple studies, suggesting curiosity about its efficacy and safety.
Several comments cite specific data points, quotes, and question the methodology, reflecting active engagement.
Discussions focus on the potential of remdesivir as a treatment, showing it could influence ongoing medical practices and opinions.
レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたのもそれが理由かも。 https://t.co/dkDozT6KWb
The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was observed in 36 of the 53 patients (68%). Remdesivir is characterized by broad spectrum activity against several virus families. https://t.co/6sbWXbus1F https://t.co/xnYsmJoROY
7/ Sökandet efter läkemedel som stoppar viruset tillväxt i kroppen pågår frenetiskt. #remdesivir har testats kliniskt med varierande resultat. Vi behöver dock veta mer, och hitta fler och säkrare #antivirala läkemedel mot #sarscov2 https://t.co/IcSlEFEGi9 https://t.co/nIWBURADLC
@HousatonicLive @Jikkyleaks @HealthUncensord @JesslovesMJK @JasonChristoff6 @RWMaloneMD @PierreKory @MidwesternDoc @P_McCulloughMD @MdBreathe @DrAseemMalhotra @BretWeinstein Well nop, I think that if a world expert in coronavirus co-authored a letter (now mysteriously missing from PubMed's search) pushing the thing days after Snohomish's detection, it may have helped. Do you have a source for DOMANE spiting it before? https://t.co/a8dA4Z6qhi https://t.co/DdOOvRthG7
12
レムデシビルφ(．．) ◆Lancet . 2020 May 16;395(10236):1569-1578. https://t.co/JsSH63wTzI ◆JAMA. 2020 Sep 15;324(11):1048-1057. https://t.co/SMa344poD1 ◆N Engl J Med . 2020 Jun 11;382(24):2327-2336. https://t.co/fxe7DpTpaJ
Since its emergence in December 2019, the world has been dealing with COVID-19, officially declared a pandemic by the WHO. This video explores Remdesivir, the first FDA-approved antiviral for COVID-19, detailing its…
FDA reports on a Phase 3 trial investigating remdesivir, an antiviral drug, in patients with severe COVID-19. The trial assessed safety and efficacy and compared outcomes with other experimental therapies, highlighting…
This presentation discusses ribavirin and interferon alpha as a low-cost, potential treatment for COVID-19, including dosage and managing side effects. It highlights encouraging results from early use and encourages…
Remdesivir Covid19 135 80 4 httpswwwgileadcom httpswwwcaixincom httpswwwsjcom httpswwwreuterscom APP httpmpweixinqq comprofilesrc3timestamp1588910778ver1signatureWuQBZj2062fY9COnA8EqWxenuWJ9MUgKYKLX7rK9bmhUxzpMmVW9ntKSgK…
Remdesivir, a nucleoside analog, inhibits viral RNA polymerase and showed activity against SARS-CoV-2 in vitro. In a study of 53 patients, 68% improved clinically, but further randomized trials are needed to confirm its…
@sukunabikonano @corowaku_memo まず「治験が1月から」これがそもそも嘘 日本が参加した治験は志村けんが亡くなった後から始まった第三相試験 じゃあ投与可能性はどうかと言うと、それも無い 主が主張する投与された期間はリンクにあるように志村けんの入院前には終わってる ここまで調べてから話入って来い https://t.co/u2ZLLYudXy https://t.co/2ACEv67qc9
@dou_nidemo_nare @corowaku_memo 何も調べてゐないのは貴殿ですよね。レムデシビルは正式承認前に臨床現場で治檢的に使はれてゐましたが何か。隱謀論を唱へるはお止め下さいｗ 正式承認前の治檢 2020年1月25日～3月7日 https://t.co/MPBOOvzBJg
@Astroco2023 @binbou415 完膚なき迄に論破されないと気が済まないのでしょうか？無料版で自動翻訳されるので、全部読みなさい。 国立国際医療研究センターの大曲先生の名前も入っている。3月7日以前に投与された日本人の対象は９名。 思い込みで失礼なお前の謝罪文を待つ事にする。 https://t.co/iGYk4CF1AB
2020年4月發布： Compassionate Use of Remdesivir for Patients with Severe Covid-19 | New England Journal of Medicine https://t.co/GDgJDeRAtY
RT @romeerizwan: Encouraging results with Remdesivir #COVID19 . ‘68% had an improvement in oxygen-support class, including 17 of 30 patient…
@RFKJr_Official @DrJBhattacharya I'm not a doc or scientist, just a widow whose husband received this 'compassionate care'. Compassionate Use of Remdesivir for Patients with Severe Covid-19 | New England Journal of Medicine https://t.co/FDydgfZnTY
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | New England Journal of Medicine Published April 10, 2020 https://t.co/sdvQduCciW
RT @dezzie_rezzie: 12
@William277907 @BarryESharp https://t.co/XrH2LYTxRw
@5miles4U @KylieJaneKremer Remdesivir was tested on Ebola patients prior to covid. Of the 4 drugs, remdesivir had the worst outcome w/ a 53.1% death rate, which is higher than the death rate from the virus. NEJM Study: https://t.co/WDbzWikyVo Compared to Ivermectin, which is safe: https://t.co/RkMxI64gON https://t.co/TKFbf52WyE
@DrNoMask Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@DrDMartinWorld Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@elonmusk @MikeBenzCyber Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@laralogan Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@LauraPowellEsq Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@c_essene @newstart_2024 Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@SharylAttkisson @HighWireTalk Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@HighWireTalk @delbigtree Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@newstart_2024 Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@nataliegwinters Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@jordanbpeterson Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@MdBreathe @P7Movie Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@goddeketal Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMXCfL
@lawrie_dr Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@BretWeinstein Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@ChildrensHD Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@_taylorhudak Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@DowdEdward Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@RobertKennedyJr @realDonaldTrump @TulsiGabbard Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@RobertKennedyJr Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@ChildrensHD @jimmy_dore Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@jimmy_dore Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@AaronKheriatyMD Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@P_McCulloughMD @WellnessForce Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@DrJBhattacharya Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@PierreKory @MidwesternDoc Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@naomirwolf @EmeraldRobinson OMG - Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wxPazMX4qd
@kyoumi_wish @FUTANOKENTAROw @mooncave3 不親切ですみません この治験は2020年3月7日までのもの、とこのブログにも書いてある通りでして、3月29日に亡くなった志村けんさんは対象外なんですよ これに関する論文が4月10日にでています https://t.co/hgdTKuZNlv
RT @canceledmouse: @HousatonicLive @Jikkyleaks @HealthUncensord @JesslovesMJK @JasonChristoff6 @RWMaloneMD @PierreKory @MidwesternDoc @P_Mc…
@HousatonicLive @Jikkyleaks @HealthUncensord @JesslovesMJK @JasonChristoff6 @RWMaloneMD @PierreKory @MidwesternDoc @P_McCulloughMD @MdBreathe @DrAseemMalhotra @BretWeinstein Well nop, I think that if a world expert in coronavirus co-authored a letter (now mysteriously missing from PubMed's search) pushing the thing days after Snohomish's detection, it may have helped. Do you have a source for DOMANE spiting it before? https://t.co/a8dA4Z6qhi https://t.co/DdOOvRthG7
@nicomorowat @KatKanada_TM You are an idi0t https://t.co/v8kRq1hmWA
@TillyandJames @KatKanada_TM https://t.co/v8kRq1hmWA
@SBeloous96837 @KatKanada_TM Lies https://t.co/v8kRq1hmWA
@DermottrobRob @KatKanada_TM https://t.co/v8kRq1hmWA
@KatKanada_TM More outright lies from Katrina https://t.co/v8kRq1hmWA
RT @dezzie_rezzie: 12
@WCCO The New England Journal of Medicine: Compassionate Use of Remdesivir for Patients with Severe Covid-19: https://t.co/48cmW0Z4Lh (NIH): Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: https://t.co/7oWlVxsEc1 https://t.co/Rd3SgU05go
@mpc_xetts @Dr_Catfarmer @Truth_in_Number "A total of 12 patients (23%) had serious adverse events. The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension" https://t.co/d700qYomDJ https://t.co/paCPJvyaca
RT @dezzie_rezzie: 12
12
RT @Rahelpath: https://t.co/h6bBpJyGxL
@mpc_xetts @mitzi1946 @AntonioTweets2 Another study published in The New England Journal of Medicine found that seven of the 53 patients (13%) died after the completion of remdesivir treatment. https://t.co/q7lga5ERSG
@dirk_fasshauer @sunshine_toes @ValZimmer2 @rubrogram @ThomMohr @kamziknahorach @lagerth13136056 @Burki677 @KStateTurk @The_Seeadler @lifestylemanoz @TakethatCt @ViroLIEgy @claushetting @ReviewingRemy @JamieAA_Again @Dirk_aus_Hessen @PChandr43659403 @sense_strand @bitcoinbumBB @SoupTomatoSoup @DrCrazynski @THC1001 @adiosmuchachos4 @DdkDav @Censored4sure @dan_gadd @Debunk_the_Funk @rw_christian @dpl003 @richdatasci @themcpaw @HealthcareGlob1 @DarrenT76334333 @ExposeThePlan @TrevorJukes1 @RameseSanders @macgyvertang20 @DAVID__BB @ine16840704 @JoeHendry696 @Alec_Zeck @andyparksmma @Fckelonmusk1 @jason_willz1 @rt7683 @holisticgrenade @SpkJayIII @MCPAW https://t.co/KAi8ZQri3z
@mpc_xetts @VigilantFox @FreightD https://t.co/yFbzbVRpHM A total of 32 patients (60%) reported adverse events during follow-up (Table 2). The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. In general, adverse events were more common in patients
RT @RStophe: @TavernTruth 3. A Study that Anthony Fauci Cited claiming that proved Remdesivir was effective. This study was conducted by th…
@TavernTruth 3. A Study that Anthony Fauci Cited claiming that proved Remdesivir was effective. This study was conducted by the manufacturer of Remdesivir. Title of Study: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wBIiw7lETT
RT @jpkiekens: @RealGeorgeWebb1 https://t.co/DaCU9ek02O
@RealGeorgeWebb1 https://t.co/DaCU9ek02O
RT @bosanskakaf: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/w0ppoLb4Pq «Seven of the 53 patients (13%)…
Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Hersteller #Gilead finanzierten, UNKONTROLLIERTEN Studie... https://t.co/3XY1eZ9vEX
RT @bosanskakaf: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/w0ppoLb4Pq «Seven of the 53 patients (13%)…
RT @bosanskakaf: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/w0ppoLb4Pq «Seven of the 53 patients (13%)…
@Project_Veritas This is NOT a scientific paper. Any such paper would have referred to prior articles such as those two - which indicated lack of both safety & effectiveness. This was before Emergency Use Authorization. But who cared at the time? https://t.co/DaCU9ekxSm https://t.co/4ccg7o2WU3 https://t.co/4sxJ6TSPhF
RT @bosanskakaf: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/w0ppoLb4Pq «Seven of the 53 patients (13%)…
Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/w0ppoLb4Pq «Seven of the 53 patients (13%) died after the completion of remdesivir treatment, including 6 of 34 patients (18%) who were receiving invasive ventilation» https://t.co/BPNddZI67g
RT @JimHB_4Liberty: @VigilantFox 23% had serious adverse events here https://t.co/KAi8ZQrPT7
@VigilantFox 23% had serious adverse events here https://t.co/KAi8ZQrPT7
First,the "compassionate" buggers did not measure viral loads,April 2020 "our compassionate-use program did not collect viral load data to confirm the antiviral effects of remdesivir or any association between baseline viral load and viral suppression” https://t.co/dbKgdsID8G
@shakemaster_B @jack @Twitter Maybe you should. https://t.co/eeVu6W07Po https://t.co/GAx3rG7SEg https://t.co/fOKwpcCsca
@SallyMayweather And here's the 2nd: https://t.co/UELjcKlAFi
Yes, I realize the covid crap is over..finally...but I just happened to run into this today. Remdesivir used for "compassionate" treatment? https://t.co/4iLTdLk9bI
@MaddowBlog 2 - Fauci quoted a second study in support of his mandating the use of Remdesivir, a study conducted by the makers of Remdesivir titled; ‘Compassionate Use of Remdesivir for Patients with Severe Covid-19‘, wherein 53 patients with C19 were administered the drug for 10 days.
@janicecarlson77 Report dr. Fauci to authorities (and not to twitter) for accepting remdesivir based on these studies: https://t.co/WE8lw8LL20 https://t.co/s72s1MQM2M If you know how to read a studies just check fatality rate!
7/- And #Fauci was citing this unsuccessful trial of #Remdesivir on only 53 #Covid19 patients along with the failed Ebola trials to get emergency use authorisation. #WTF What do the TGA do? What papers did they study for 2 wks to approve a failed drug? https://t.co/BAzxfvKGsV
@ElisMadison @Beautyjunkie21 @jenneraub They did it for $. Cms incentivized it& administrators threatened drs who wanted to treat differently. I have my own personal experience but if you want data here's remdesivir's:https://t.co/BgA5bTv6Jp https://t.co/VGCMFzKEhh
Couple of morons from Brazil finds it doesn't work, hey look, it's published in @NEJM Ironically, so is this: https://t.co/isTRulAL3f 53% of Remdesiver patients, well ... didn't make it and this https://t.co/VtyQd0mgjM 13% of them "didn't make it" But it's recommended
RT @Elarab_1: @medicalfollower @SoMabrouk @olivierveran oublie t il que son conseiller direct F. X. Lescure est un promoteur du Remdesivir…
@medicalfollower @SoMabrouk @olivierveran oublie t il que son conseiller direct F. X. Lescure est un promoteur du Remdesivir https://t.co/osX5O8YoJb https://t.co/UrLv2kzmoW et aussi 27/07/2020 https://t.co/YG8TzWoseY Voir les noms dans les sources : Bruno Lina1,6, Yazdan Yazdanpanah7,8
@ToddFuller0418 @SexCounseling https://t.co/VGCMFzKEhh https://t.co/BgA5bTv6Jp
Gilead began trialing RDV via compassionate use in early spring 2020. These trials were published in @NEJM & @JAMA_current & were heavily criticized for lack of a control arm & inability to draw conclusions on RDV's utility for hospitalized patients 4/10 https://t.co/mjSXwXsrCp
@HawkeyeUofIA @Awithonelison Also because I care…please review these studies on Remdesivir and ask your doctor questions..
23% of remdesivir trial patients had serious ADR of multiple organ failure or kidney disease, when ventilated. What did hospitalised covid patients die of? What were they being treated with? https://t.co/OZja6aywYC https://t.co/qoSnZWx7Kh https://t.co/EgYGtOMmfF
RT @kidney_boy: Ladies and gentleman, I think we have a therapy. https://t.co/QpN0tKFSfo https://t.co/WDCpgLwU0A
RT @kidney_boy: Ladies and gentleman, I think we have a therapy. https://t.co/QpN0tKFSfo https://t.co/WDCpgLwU0A
RT @kidney_boy: Ladies and gentleman, I think we have a therapy. https://t.co/QpN0tKFSfo https://t.co/WDCpgLwU0A
DO NOT,I REPEAT,DO NOT ALLOW YOUR HOSPITALIZED LOVED ONES ON REMDESIVIR! ITS 50%FATAL BY CAUSING MULTI ORGAN FAILURE. IF THE PT SURVIVES,30% CHANCE OF SEVERE KIDNEY FAILURE.The NIH DOES allow ivm for covid! https://t.co/BgA5bTv6Jp https://t.co/VGCMFzKEhh https://t.co/LHzDgjvnoV
@Panagio22233108 @Perseas_Mi Διάβασε λιγο αγορινα μου το safety https://t.co/HHOlxrVtm2
@kevinrschultz @MalBulmer @BarryCPearson @zoeharcombe https://t.co/VGCMFzKEhh
@ViolaAppleton6 @rick_pittman And this one https://t.co/5htMU3WfNH
@En_kef @Technomagos @machiavelli_gr Doctor
RT @sanchak74: The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few pati…
RT @sanchak74: The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few pati…
RT @sanchak74: The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few pati…
RT @sanchak74: The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few pati…
RT @sanchak74: The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few pati…
The worst is there is no proof the Remdesivir reduces viral load - they just did'nt measure, they cant do PCR for a few patients. Imagine that April 2020 NEJM https://t.co/C9PRej1b6q (22 authors with Gilead conflict) Aug Jama https://t.co/sDXVShwezW https://t.co/zXWp3oWqi9 https://t.co/PmZfMwh5ee
RT @zchagla: Let's review the history of Remdesivir 1) Jan-Feb - COVID hits the world - remdesivir is an interesting compound that needs a…
@swelenc @EveDallas11557 @InfinityHealth8 And as Ive shown, remdesivir helps as do ventilators when youre up against it. https://t.co/xyMAefE0Wt https://t.co/8UqV8GccOa https://t.co/BBRplGTdMq
@swelenc @EveDallas11557 @InfinityHealth8 As per, https://t.co/8UqV8GccOa And https://t.co/xyMAefE0Wt
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: After Remdesivir treatment: "A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18%…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
RT @TheBernician: 100-200mg of Remdesivir, administered over 1-10 days, is known to kill 13% of 'COVID patients' - the same as the MHRA app…
https://t.co/mTALVEJ1ps
@pablostockbar While Ebola is different, look at the mortality rate of people were on remdesivir. Remdesivir is what people are using in the hospitals. https://t.co/aOwKWXhoR0 https://t.co/wg5j9gXq1M
@KanchanGupta Remdesivir is used for patients with severe Covid-19. Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV2 There is an article published in the New England Journal of Medicine (NEJM) https://t.co/DKO7jo7CuO
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/DRjBTfK6T7
@OceAlaB @Regis1606 @saphorocoeur @valerieboyer13 @raoult_didier En faveur avant septembre https://t.co/mIMiwzbms6 https://t.co/8rmJ8NqHS0 https://t.co/Lz61mEXSau et au moins deux autres RCT en octobre si on prend en compte SOLIDARITY
@nathanpsmad @NIH @WHO @Inserm @GileadSciences @afis_science J’avais lu ces effets indésirables reportés dans l’étude NEJM « Compassionate Use of Remdesivir for Patients with Severe Covid-19 ». Certains rapport font également état de potentiels toxicité rénale. https://t.co/s5NsaJd2ox
@DegrafH @DocPepperFR @x_xdir Elle était publié en pre-print le 10 avril, il a écrit le passage précédent le 14 avril. On peut lui reprocher beaucoup de choses mais il lit la littérature. préprint: https://t.co/Hf3M2pOYt1
RT @Fizz_DI: レムデシビルφ(．．) ◆Lancet . 2020 May 16;395(10236):1569-1578. https://t.co/JsSH63wTzI ◆JAMA. 2020 Sep 15;324(11):1048-1057. https:…
RT @Fizz_DI: レムデシビルφ(．．) ◆Lancet . 2020 May 16;395(10236):1569-1578. https://t.co/JsSH63wTzI ◆JAMA. 2020 Sep 15;324(11):1048-1057. https:…
レムデシビルφ(．．) ◆Lancet . 2020 May 16;395(10236):1569-1578. https://t.co/JsSH63wTzI ◆JAMA. 2020 Sep 15;324(11):1048-1057. https://t.co/SMa344poD1 ◆N Engl J Med . 2020 Jun 11;382(24):2327-2336. https://t.co/fxe7DpTpaJ
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | Should use all serious cases @FDA needs to wake up https://t.co/bvJdUpeb77
New England Journal of Medicine: Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/WH6hqemAVI
RT @Smackenziekerr: https://t.co/tWzUxj5NPg https://t.co/p912fEdi0D
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/Fl1IkCjazY
68%で酸素投与の改善が見られ、死亡率は13%と他の報告よりも低い数値となっていました。 Grein J et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 2020. https://t.co/vTILFlxeyn
COVID19に対しての初期のレムデシビル論文はこちらです。解析対象は重症患者53人と少なく対称群がない、という限られた中でのエビデンスですが、有用性が示唆されています。 Grein J et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 2020.
https://t.co/tWzUxj5NPg https://t.co/p912fEdi0D
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/fIq3M4pC2d
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/sZqytsrKcu
RT @janlotvall: 7/ Sökandet efter läkemedel som stoppar viruset tillväxt i kroppen pågår frenetiskt. #remdesivir har testats kliniskt med v…
RT @janlotvall: 7/ Sökandet efter läkemedel som stoppar viruset tillväxt i kroppen pågår frenetiskt. #remdesivir har testats kliniskt med v…
RT @janlotvall: 7/ Sökandet efter läkemedel som stoppar viruset tillväxt i kroppen pågår frenetiskt. #remdesivir har testats kliniskt med v…
7/ Sökandet efter läkemedel som stoppar viruset tillväxt i kroppen pågår frenetiskt. #remdesivir har testats kliniskt med varierande resultat. Vi behöver dock veta mer, och hitta fler och säkrare #antivirala läkemedel mot #sarscov2 https://t.co/IcSlEFEGi9 https://t.co/nIWBURADLC
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/KAEytxJONy
@Sid2001 @kkmick19 @AdamHykes @JamesTodaroMD Here is another: https://t.co/7NGW8sePx4
Compassionate Use of Remdesivir for Patients with Severe Covid-19. https://t.co/qzrQsJJcMm
@moylea @gtiso @OverlandJournal so far there's been this study of 53 people. no RCT even yet to prove its efficacy, please don't jump the gun. we don't even know if this works yet. https://t.co/wHq3Kw9BdU
RT @kyudai1news: 有望な薬が徐々に判明します。 Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/8JXogFEmi8
expert reaction to a study about compassionate use of remdesivir for patients with severe COVID-19 | Science Media Centre https://t.co/g0Nddn5iZp
Compassionate Use of Remdesivir for Patients with Severe Covid-19 - https://t.co/kk16BhrVAW
#Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/kEJl9A7j86 #science
@Martinvadlenka2 @Yerycho @FrMatejka @Telicka Compassionate use of remdesivir for patients with severe Covid-19 ,New England Journal of Medicine 382 (24), 2327-2336, 2020. To je zatím poslední, ale vlastně nevím kolik si představujete odborných článků na téma: ojedinělý lék a 6 měsíců trvající pandemie...
RT @buzzingscience: #science #STEM Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/ciwTajRREf https:/…
#science #STEM Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/ciwTajRREf https://t.co/klPr9UGnbW
日本では特例承認という形で話題に。現在のような未曾有の危機でこそ批判的吟味のスキルが生きてくるかもしれません 重症COVID-19患者に対するレムデシビル(ベクルリー®)の人道的使用 Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/MTE5tXl1Ua
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/hWfWR9VdPl REMDESIVIR
RT @WaltiSiegrist: Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Herstel…
Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Hersteller (Gilead) finanzierten, UNKONTROLLIERTEN Studie... https://t.co/sdSAe205wu
https://t.co/LGixp8soz5 › doi › full Web results Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM
@_D2_C2 @kishorchitra @ShashiTharoor @WHO @TheWire Gilead”s Remdesivir (RNA pol inhibitor) 1. Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/Cmrb53owc7 2. Two-thirds of coronavirus patients improve after using remdesivir: study- New York Post https://t.co/uNZTUygDn1
https://t.co/ngSD39WHrx
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/7Kq0940sM5
RT @fermarti_1: Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/d6EyH1IMPd
重症 Covid-19 患者に対する未承認薬レムデシビルの人道的使用 Compassionate Use of Remdesivir for Patients with Severe Covid-19 The New England Journal of Medicine（日本国内版） https://t.co/DUAf1YCwLl
The evidence is very slowly building. Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM @YetenaW @fitse_t @alulamd @FitsumberhanG @ErmiasMd @adbelete https://t.co/kzXgKLlIcI
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/w2z3bib6XF
RT @ChristianCombe: @FZores @bentatoo31 @fluidloading Le NEJM n'a pas publié la lettre que nous lui avons adressée avec Thierry Maisonneuve…
RT @ChristianCombe: @FZores @bentatoo31 @fluidloading Le NEJM n'a pas publié la lettre que nous lui avons adressée avec Thierry Maisonneuve…
@FZores @bentatoo31 @fluidloading Le NEJM n'a pas publié la lettre que nous lui avons adressée avec Thierry Maisonneuve et Mathieu Molimard. La voici sur Twitter: Compassionate Use of Remdesivir for Patients with Severe Covid-19. In the context of urgency of the COVID-19, the Journal is first for providing 1/n
@jdceulaer @thebandb @vanranstmarc @mkeulemans het op maat van covid antwoord is: open scholen OK, want de spreiding gaat door tot groepsimmuniteit, Conditie zou moeten zijn: REMDESIVIR is beschikbaar in BELGIE https://t.co/B7NckDMDlR Wanneer keurt halen we remdesivir in ons behandelingspalet ?
Artículo original: https://t.co/FEv4RnYAv3
Compassionate Use of Remdesivir for Patients with Severe Covid-19 – https://t.co/WV1KXSxHqR https://t.co/PcMpuiU6lL
RT @K7Joseph: Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/07ggVxd2vq DOI: 10.1056 / NEJMoa2007016
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/07ggVxd2vq DOI: 10.1056 / NEJMoa2007016
Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/gtBGIu8cWf Pub: 10 Apr
Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://t.co/wwqwpuauVw
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020. 28/28
Compassionate Use of #Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/RzBAyMGm58
Title of study Compassionate Use of Remdesivir for Patients with Severe Covid-19 NEJM https://t.co/1TlsidfD4X
RT @2minmed: #VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19 https://t.co/dEtYS05YPR #StudyGraphics #com…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @2minmed: #VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19 https://t.co/dEtYS05YPR #StudyGraphics #com…
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/QQL9MTJXtQ
RT @2minmed: #VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19 https://t.co/dEtYS05YPR #StudyGraphics #com…
#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19 https://t.co/dEtYS05YPR #StudyGraphics #compassionateuse https://t.co/ZaAob9ZoMM
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/x5kU8G1YJa
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
RT @NEJM: In this letter, the authors discuss the Correspondence “Compassionate Use of Remdesivir for Patients with Severe Covid-19” by Gre…
@Scheibenwischan Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Hersteller (Gilead) finanzierten, UNKONTROLLIERTEN Studie... https://t.co/sdSAe205wu
Remdesivir “人民的希望”瑞德西韦 定价区间10美元~4500美元 https://t.co/xI3Rt4JZ1C 来自 @YouTube
RT @WaltiSiegrist: Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Herstel…
Ich begreife das Unbehagen gegen Teile der Schulmedizin. "Bibel" , New England Journal of Medicine: In einer vom Hersteller (Gilead) finanzierten, UNKONTROLLIERTEN Studie... https://t.co/sdSAe205wu
@docneto Here's another article but the sample size is smaller than in the previous article and the criteria to define "improvement" is different. https://t.co/eDjx787wHQ
https://t.co/9LhOIzyFjW
RT @MedicalScitech:
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/AO6K7oqIKm
Da gerade viel über #Remdesivir in den Medien berichtet wird, hier eine Studie zum nachlesen... Spoiler: es ist keine Wunderwaffe, aber es kann helfen, in dieser Studie zumindest zu 68% Compassionate Use of Remdesivir for Patients with Severe Covid-19. https://t.co/XSVJtcbnlM
RT @TANIGUCHIH3: Compassionate Use of Remdesivir for Patients With Severe Covid-19 - PubMed コロナ肺炎に対するレミデシビル 日本でも特例承認制度を使い5月上旬にも承認されそう。重症者にも…
Compassionate Use of Remdesivir for Patients With Severe Covid-19 - PubMed コロナ肺炎に対するレミデシビル 日本でも特例承認制度を使い5月上旬にも承認されそう。重症者にも期待できそう- 呼吸器専門医 https://t.co/F11pHdzFtA
@neogaia21 https://t.co/BrtDJKtcFX まー、完治薬ではなさそうですが、重症例に少しは効きそうな期待を。
抗ウイルス新薬 Remdesivirのコホート研究 まだ臨床での安全性は確立していませんが https://t.co/nqi54RlFQ9
3/Here's the link to this article in @NEJM https://t.co/o7je6ZVaOR And the link to our #EmoryID fellows' scholar blog w/ other lit summaries, visual abstracts & infographics created by our medical students. https://t.co/zwJZ7oCkyv
https://t.co/IpkEP2E87H #remdesivir @GileadSciences $GILD .. I don't currently hold any $GILD stock but if it comes down further.. I'll buy a block of it. #ES_F
este es el trabajo que, creo, más se mostró en los medios: Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19 https://t.co/qnH4E4Vg0T
https://t.co/GEyDIGydl8 Compassionate Use of Remdesivir for Patients with Severe Covid-19
なるほど！ #COVID19 #NEJM https://t.co/6IZVrQ6gVY
RT @sinwanohate: 論文：ウイルスのRNAポリメラーゼ阻害剤レムデシビルが、新型コロナ患者に効くかもしれない。被験者53人中7割近くが改善、人工呼吸器をつけていた患者の半数以上も。ただし、亡くなった人も7人。日本人患者9人もテストに参加。 https://t.co…
RT @sinwanohate: 論文：ウイルスのRNAポリメラーゼ阻害剤レムデシビルが、新型コロナ患者に効くかもしれない。被験者53人中7割近くが改善、人工呼吸器をつけていた患者の半数以上も。ただし、亡くなった人も7人。日本人患者9人もテストに参加。 https://t.co…
https://www.nejm.org/doi/full/10.1056/NEJMoa2007016?query=featured_coronavirus
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/nCBhVDycEj
RT @sinwanohate: 論文：ウイルスのRNAポリメラーゼ阻害剤レムデシビルが、新型コロナ患者に効くかもしれない。被験者53人中7割近くが改善、人工呼吸器をつけていた患者の半数以上も。ただし、亡くなった人も7人。日本人患者9人もテストに参加。 https://t.co…
論文：ウイルスのRNAポリメラーゼ阻害剤レムデシビルが、新型コロナ患者に効くかもしれない。被験者53人中7割近くが改善、人工呼吸器をつけていた患者の半数以上も。ただし、亡くなった人も7人。日本人患者9人もテストに参加。 https://t.co/15vsoj7Au3
新型コロナウイルス「レムデシビル」が効くか？ランダム化比較試験ではなく、あくまでも後方視点的解析であることに注意は必要だが、Covid-19に対して、有益である可能性を有する薬剤が出てきた。ただ効果がなかった患者に対する考察がもう少し欲しいな。 https://t.co/09wAo7E6GS
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
https://t.co/uVrzT9aNFB
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
Promising... https://t.co/hypXSJl6pd
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/uv4sqmmSdt
Uso compasivo de remdesivir en pacientes con COVID19 grave. Se observó un 63% de mejoría clinica. Dosis: 200 mg inicial, seguido de 9 días 100 mg/24 hrs | NEJM https://t.co/lu80YAVUzS
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
Remdesivir shows clinical improvement in 84% of severely-ill COVID-19 patients within one month of treatment. #science https://t.co/CBH58DrgD7 @NEJM paper: https://t.co/HbILyt1a7M
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
RT @CristinaDragani: The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was ob…
The #antiviral #remdesivir showed clinical usefulness for patients with severe #COVID19. A clinical improvement was observed in 36 of the 53 patients (68%). Remdesivir is characterized by broad spectrum activity against several virus families. https://t.co/6sbWXbus1F https://t.co/xnYsmJoROY
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
RT @influenzer3: レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたの…
レムデシビルの効果に関する報告 →NEJMに有望な成績が報告されています。 それでも、私の認識ではRCTはもちろんcase control studyすらまだかと思います。 最近紹介したATSガイドで｢no suggestion｣になっていたのもそれが理由かも。 https://t.co/dkDozT6KWb
https://t.co/nQMEHzbPV7
Ladies and gentleman, I think we have a therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
Un estudio también reciente (aunque con varias limitaciones) para el uso compasivo de #remdesivir en 53 pacientes graves con #COVIDー19, encontró una mejoría clínica en el 68% para el parámetro de soporte de oxígeno y una mortalidad del 13%. https://t.co/uqO3jlp4Ve https://t.co/SqDhHqKglt
DK
C